These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1145 related articles for article (PubMed ID: 10661346)

  • 21. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.
    Kupelian PA; Reddy CA; Klein EA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):988-93. PubMed ID: 11704322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect.
    Lee WR; Hanks GE; Hanlon AL; Schultheiss TE; Hunt MA
    Int J Radiat Oncol Biol Phys; 1996 May; 35(2):251-7. PubMed ID: 8635930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland.
    Mohan DS; Kupelian PA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):575-80. PubMed ID: 10701736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms.
    Boersma LJ; van den Brink M; Bruce AM; Shouman T; Gras L; te Velde A; Lebesque JV
    Int J Radiat Oncol Biol Phys; 1998 Apr; 41(1):83-92. PubMed ID: 9588921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison.
    Perez CA; Michalski JM; Purdy JA; Wasserman TH; Williams K; Lockett MA
    Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):629-37. PubMed ID: 10837945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy.
    Chou RH; Wilder RB; Ji M; Ryu JK; Leigh BR; Earle JD; Doggett RL; Kubo HD; Roach M; deVere White RW
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):115-9. PubMed ID: 10758312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.
    Ashman JB; Zelefsky MJ; Hunt MS; Leibel SA; Fuks Z
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):765-71. PubMed ID: 15913914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.
    Dolezel M; Odrazka K; Vaculikova M; Vanasek J; Sefrova J; Paluska P; Zouhar M; Jansa J; Macingova Z; Jarosova L; Brodak M; Moravek P; Hartmann I
    Strahlenther Onkol; 2010 Apr; 186(4):197-202. PubMed ID: 20354663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.
    Thor M; Deasy JO; Paulus R; Robert Lee W; Amin MB; Bruner DW; Low DA; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Gore EM; Albert M; Pisansky TM; Faria SL; Chen Y; Koontz BF; Swanson GP; Pugh SL; Sandler HM
    Radiother Oncol; 2019 Jun; 135():19-24. PubMed ID: 31015166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
    Karlsdóttir A; Johannessen DC; Muren LP; Wentzel-Larsen T; Dahl O
    Radiother Oncol; 2004 Apr; 71(1):43-53. PubMed ID: 15066295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer.
    Huang EH; Pollack A; Levy L; Starkschall G; Dong L; Rosen I; Kuban DA
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1314-21. PubMed ID: 12459352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
    Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
    JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
    Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial.
    Bruner DW; Hunt D; Michalski JM; Bosch WR; Galvin JM; Amin M; Xiao C; Bahary JP; Patel M; Chafe S; Rodrigues G; Lau H; Duclos M; Baikadi M; Deshmukh S; Sandler HM
    Cancer; 2015 Jul; 121(14):2422-30. PubMed ID: 25847819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
    Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC
    Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.